Marshall Wace
TBPH icon

Marshall Wace’s Theravance Biopharma TBPH Stock Holding History

Marshall Wace’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.21M Buy
188,748
+29,848
+19% +$494K ﹤0.01% 1596
2026
Q1 		$2.58M Sell
158,900
-259,729
-62% -$4.59M ﹤0.01% 1641
2025
Q4 		$7.83M Buy
418,629
+60,978
+17% +$1.01M 0.01% 964
2025
Q3 		$5.22M Buy
357,651
+256,873
+255% +$3.25M 0.01% 1169
2025
Q2 		$1.11M Buy
100,778
+85,867
+576% +$835K ﹤0.01% 1800
2025
Q1 		$133K Sell
14,911
-51,156
-77% -$476K ﹤0.01% 2464
2024
Q4 		$622K Sell
66,067
-83,993
-56% -$764K ﹤0.01% 1954
2024
Q3 		$1.21M Sell
150,060
-147,439
-50% -$1.28M ﹤0.01% 1572
2024
Q2 		$2.52M Buy
297,499
+135,426
+84% +$1.22M ﹤0.01% 1263
2024
Q1 		$1.45M Buy
+162,073
New +$1.5M ﹤0.01% 1503
2023
Q4 		– Sell
-20,400
Closed -$176K – 2601
2023
Q3 		$176K Sell
20,400
-39,412
-66% -$380K ﹤0.01% 1996
2023
Q2 		$619K Buy
+59,812
New +$660K ﹤0.01% 1906
2020
Q3 		– Sell
-14,990
Closed -$315K – 1917
2020
Q2 		$315K Buy
+14,990
New +$385K ﹤0.01% 1314
2019
Q2 		– Sell
-4,080
Closed -$92K – 1825
2019
Q1 		$92K Hold
4,080
– – ﹤0.01% 1447
2018
Q4 		$104K Buy
+4,080
New +$110K ﹤0.01% 1361
2017
Q1 		– Sell
-408,880
Closed -$13M – 716
2016
Q4 		$13M Buy
408,880
+329,812
+417% +$10.2M 0.09% 267
2016
Q3 		$2.87M Buy
79,068
+55,362
+234% +$1.54M 0.02% 518
2016
Q2 		$538K Buy
+23,706
New +$512K ﹤0.01% 814

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Marshall Wace's TBPH Position: Q2 2026 in Review

Marshall Wace increased its Theravance Biopharma (TBPH) stake by 19% in Q2 2026, buying an estimated $494K and bringing the position to 188,748 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1596.

Marshall Wace first reported a position in TBPH in Q2 2016 and has held it in 18 quarters since. The position peaked at $13M in Q4 2016. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Marshall Wace held 188,748 shares of Theravance Biopharma worth $3.21M as of Q2 2026.
  • Marshall Wace bought 29,848 Theravance Biopharma shares in Q2 2026, an estimated $494K.
  • Theravance Biopharma made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1596 holding.
  • Marshall Wace first reported a position in Theravance Biopharma in Q2 2016 and has held it in 18 quarters since.
  • Marshall Wace's Theravance Biopharma position peaked at $13M in Q4 2016.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.